Doximity (DOCS) shares fell 24% after the company posted mixed Q4 results and issued a weaker outlook for FY2027, which led several analysts to cut their ratings. The sell-off reflects rising concern that the company’s steady growth is slowing while competition and AI-related costs rise. Wells Fargo analyst Stan Berenshteyn lowered his rating to Hold and cut his price target to $18 (0.14% upside), the lowest on the Street.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Doximity is an online networking service for medical professionals.
Wells Fargo Flags Three Big Risks for Doximity
Wells Fargo’s Berenshteyn downgraded Doximity stock to Hold from Buy and slashed the price target to $18 from $32. The analyst highlighted three key risks:
- Doximity is Falling Behind in AI Tools: Wells Fargo’s survey showed Doximity is trailing rivals even though the company is leaning more on AI to boost use and make more money.
- AI Investments Hurt Margins: The firm said Doximity’s shift toward AI search makes sense on paper, but it carries high execution risk. Also, compute costs are rising before the company sees any real revenue benefit.
- Higher Odds Doximity Loses Share: Berenshteyn warned that in a “winner-takes-most” market, Doximity is more likely to lose provider engagement to stronger AI-driven rivals than win back the lead.
BTIG Points to Weakness Ahead
BTIG analyst David Larsen also cut the stock to Hold, pointing to a much weaker FY2027 outlook. The analyst said Doximity had once hinted at getting back to double-digit growth by late 2026, but that now seems unlikely. Larsen also cited a tough macro backdrop, soft pharma demand, and clients who are slow to sign long-term deals, along with rising competition from platforms such as Veeva Systems (VEEV).
Is DOCS a Good Stock to Buy?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on DOCS stock based on nine Buys and 11 Holds assigned in the past three months. Further, the average Doximity price target of $28.12 per share implies 56.91% upside potential.
